{"id":5500,"date":"2022-09-27T08:32:57","date_gmt":"2022-09-27T15:32:57","guid":{"rendered":"https:\/\/allocare.caredx.com\/?p=5500"},"modified":"2022-09-27T08:33:05","modified_gmt":"2022-09-27T15:33:05","slug":"transplant-patients-experience-less-pain-and-fewer-adverse-events-with-caredx-non-invasive-testing-solutions","status":"publish","type":"post","link":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/indexphp\/post\/2022\/09\/27\/transplant-patients-experience-less-pain-and-fewer-adverse-events-with-caredx-non-invasive-testing-solutions\/","title":{"rendered":"Transplant Patients Experience Less Pain and Fewer Adverse Events with CareDx Non-Invasive Testing Solutions"},"content":{"rendered":"<span class=\"simplefavorite-button has-count loading\" data-postid=\"5500\" data-siteid=\"1\" data-groupid=\"1\" data-favoritecount=\"0\" style=\"\">Loading<span class=\"sf-icon-spinner-wrapper\"><i class=\"sf-icon-spinner\"><\/i><\/span><\/span>\n<p><em>Study Reaffirms Benefits of AlloMap, the Industry\u2019s Only Gene-Expression Profiling Blood Test, for Heart Transplant Rejection Surveillance<\/em><\/p>\n\n\n\n<p>BRISBANE, Calif.&#8211;(BUSINESS WIRE)&#8211;\u00a0CareDx, Inc. (Nasdaq: CDNA) \u2013 The Transplant Company\u2122 focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers \u2013 today announced a new peer-reviewed publication showing that AlloMap<sup>\u00ae<\/sup>, the industry\u2019s only gene-expression profiling (GEP) blood test to non-invasively assess graft rejection by monitoring immune quiescence in heart transplant patients,<sup>1<\/sup>\u00a0resulted in less pain and fewer adverse events compared to heart biopsy.<sup>2<\/sup>\u00a0The study also highlights that the associated AlloMap blood test draw can be performed in the patient\u2019s home to help reduce the risk of exposure to infection. <a href=\"https:\/\/investors.caredx.com\/news\/news-details\/2022\/Transplant-Patients-Experience-Less-Pain-and-Fewer-Adverse-Events-with-CareDx-Non-Invasive-Testing-Solutions\/default.aspx\">Read the complete press release<\/a> on CareDx.com.<\/p>\n<span class=\"simplefavorite-button has-count loading\" data-postid=\"5500\" data-siteid=\"1\" data-groupid=\"1\" data-favoritecount=\"0\" style=\"\">Loading<span class=\"sf-icon-spinner-wrapper\"><i class=\"sf-icon-spinner\"><\/i><\/span><\/span>","protected":false},"excerpt":{"rendered":"<p>Loading Study Reaffirms Benefits of AlloMap, the Industry\u2019s Only Gene-Expression Profiling Blood Test, for Heart Transplant Rejection Surveillance BRISBANE, Calif.&#8211;(BUSINESS WIRE)&#8211;\u00a0CareDx, Inc. (Nasdaq: CDNA) \u2013 The Transplant Company\u2122 focused on &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/indexphp\/post\/2022\/09\/27\/transplant-patients-experience-less-pain-and-fewer-adverse-events-with-caredx-non-invasive-testing-solutions\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Transplant Patients Experience Less Pain and Fewer Adverse Events with CareDx Non-Invasive Testing Solutions&#8221;<\/span><\/a><\/p>\n","protected":false},"author":208,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_EventAllDay":false,"_EventTimezone":"","_EventStartDate":"","_EventEndDate":"","_EventStartDateUTC":"","_EventEndDateUTC":"","_EventShowMap":false,"_EventShowMapLink":false,"_EventURL":"","_EventCost":"","_EventCostDescription":"","_EventCurrencySymbol":"","_EventCurrencyCode":"","_EventCurrencyPosition":"","_EventDateTimeSeparator":"","_EventTimeRangeSeparator":"","_EventOrganizerID":[],"_EventVenueID":0,"_OrganizerEmail":"","_OrganizerPhone":"","_OrganizerWebsite":"","_VenueAddress":"","_VenueCity":"","_VenueCountry":"","_VenueProvince":"","_VenueZip":"","_VenuePhone":"","_VenueURL":"","_VenueStateProvince":"","_VenueLat":"","_VenueLng":"","_tribe_blocks_recurrence_rules":"","_tribe_blocks_recurrence_description":"","_tribe_blocks_recurrence_exclusions":"","_ecp_custom_2":"","footnotes":""},"categories":[344],"tags":[66,1100],"post_format":[],"Dislikes":"","Likes":"","simplefavorites_count":"","views":"1306","post_likes_plusCounter":"","post_dislikes_plusCounter":"","acf":[],"_links":{"self":[{"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/posts\/5500"}],"collection":[{"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/users\/208"}],"replies":[{"embeddable":true,"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/comments?post=5500"}],"version-history":[{"count":1,"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/posts\/5500\/revisions"}],"predecessor-version":[{"id":5501,"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/posts\/5500\/revisions\/5501"}],"wp:attachment":[{"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/media?parent=5500"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/categories?post=5500"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/tags?post=5500"},{"taxonomy":"post_format","embeddable":true,"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/post_format?post=5500"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}